AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
NCT07555730 on ClinicalTrials.gov · last registry update 2026-04-29
An unusually large phase 4: 400 participants, more than double the 72 typical for the stage. Due to report 30 September 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Body weight change (kg). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Huazhong University of Science and Technology
- Sponsor type
- Other
- Enrollment
- 400
- Started
- 2026-04-30
- Primary completion
- 2028-09-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Body weight change (kg)
Conditions studied
Overweight or Obesity; Type 2 Diabetes · Weight Loss Maintenance
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.